In atherosclerosis and Alzheimer's disease, deposition of the altered self components oxidized low-density lipoprotein (LDL) and amyloid- triggers a protracted sterile inflammatory response. Although chronic stimulation of the innate immune system is believed to underlie the pathology of these diseases, the molecular mechanisms of activation remain unclear. Here we show that oxidized LDL and amyloid- trigger inflammatory signaling through a heterodimer of Toll-like receptors 4 and 6. Assembly of this newly identified heterodimer is regulated by signals from the scavenger receptor CD36, a common receptor for these disparate ligands. Our results identify CD36-TLR4-TLR6 activation as a common molecular mechanism by which atherogenic lipids and amyloid- stimulate sterile inflammation and suggest a new model of TLR heterodimerization triggered by coreceptor signaling events.
The innate immune system protects the organism by discriminating molecular structures that are normally absent in the healthy host. Sensing of microbial or modified endogenous ligands is mediated by germ line-encoded pattern recognition receptors, such as the scavenger and Toll-like receptors (TLRs), which recognize conserved nonself motifs 1 . Over the last decade, intense study of the mammalian TLRs has illuminated their critical role in the transcriptional regulation of genes essential for host defense against pathogens. The 12 members of this family are characterized by an extracellular leucine-rich repeat (LRR) domain and a cytoplasmic Toll-interleukin-1 receptor (TIR) domain that initiates signal transduction 2 . Upon activation, TLR signaling is propagated by recruitment of TIR-containing adaptor molecules such as MyD88, TIRAP (also called MAL), TRIF and TRAM that link to conserved signaling pathways activating NF-κB-and interferonregulated genes 2 . While these downstream signaling pathways have been well defined, the mechanisms facilitating ligand recognition by the TLRs remain poorly understood.
A notable aspect of the mammalian TLR family is the ability of this restricted group of receptors to recognize a wide range of pathogen ligands from bacteria, viruses, fungi and protozoa, including lipopolysaccharide (LPS), flagellin, CpG DNA and viral RNA 2 . Although the early identification of TLR2-TLR1 and TLR2-TLR6 (A002298) heterodimers led to the speculation that combinatorial signaling among the TLRs might account for the breadth of this repertoire 3 , no other functional TLR heterodimers have yet been described. However, the recent identification of coreceptors that enhance TLR function suggests an emerging paradigm in which TLRs act together with other cell surface molecules to bridge microbe recognition and initiation of signaling responses. A prime example of this is the well-studied TLR4 (A002296) coreceptor CD14, which acts with soluble components such as LPS-binding protein and MD-2 to recognize LPS 1 .
The class B scavenger receptor CD36 (A000560), as well as Dectin-1, integrin β 3 and mannose binding lectin, can coordinate responses to TLR2 agonists [4] [5] [6] [7] [8] . CD36 is an archetypal pattern recognition receptor that binds polyanionic ligands of both pathogen and self origin. In addition to its recently ascribed function as a TLR2-TLR6 coreceptor for Staphylococcus aureus-derived lipoteichoic acid (LTA) and Mycoplasma macrophage-activating lipopeptide-2 (MALP-2) 4,5 , CD36 has established roles in the endocytic uptake of altered self components, including oxidized phospholipids, apoptotic cells and amyloid proteins 9 . While important for the clearance of these host molecules from the circulation and tissues, CD36-dependent signaling has also been implicated in the pro-inflammatory effects of these modified endogenous ligands [10] [11] [12] [13] . These observations led us to investigate whether CD36 cooperates with members of the TLR family to activate the innate immune response to sterile ligands that accumulate in atherosclerosis and Alzheimer's disease plaques.
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A r t i c l e s
We demonstrate that recognition of oxidized low density lipoprotein (LDL) and amyloid-β peptide by CD36 triggers assembly of a heterotrimeric complex composed of CD36, TLR4 and TLR6. Of particular note, we determine that the earliest event in this inflammatory cascade is not ligation of the TLRs but rather CD36-mediated recognition, which signals through Src kinases to induce a previously undescribed TLR heterodimer of TLR4 and TLR6. TLR4-TLR6 signaling is propagated by both the MyD88 and TRIF adaptors, leading to the induction of pro-inflammatory mediators implicated in the deleterious effects of oxidized LDL (oxLDL) and amyloid-β in vivo, including the neurotoxicity that is pathognomonic of Alzheimer's disease. These results identify a common molecular mechanism underlying innate immune activation in atherosclerosis and Alzheimer's disease. Moreover, our data suggest a new model of TLR heterodimerization, regulated by signals from CD36 acting as the common ligand-binding receptor for oxLDL and amyloid-β. These observations support the notion that coreceptors can facilitate assembly of certain TLR heterodimers, and suggest that others may be identified if, as we demonstrate herein, the TLRs are coexpressed with the relevant coreceptors.
RESULTS

Cooperative signaling of TLR4 and TLR6
Lipoproteins accumulate abnormally in the artery wall during hypercholesterolemia, setting off a cascade of pro-inflammatory events, particularly the expression of chemokines that initiate an influx of monocytes 14 . Although this inflammation is sterile in nature, production of these inflammatory mediators requires the common Tollinterleukin-1 receptor signaling adaptor MyD88 (refs. 15, 16) . To search for the upstream TLRs required for proatherosclerotic chemokine production, we stimulated macrophages deficient in various TLRs with a key inflammatory component of atherosclerotic plaques, oxLDL. Array screening of a complete panel of chemokines identified four genes induced by oxLDL but not native LDL (Supplementary Fig. 1 ) in wild-type macrophages (Supplementary Table 1 ). In response to oxLDL, these cells showed 3-to 30-fold increases in mRNAs encoding Gro1 (Cxcl1), MIP-2 (Cxcl2), MIP-1γ (Ccl9) and RANTES (Ccl5) (Fig. 1a) . By contrast, macrophages deficient in TLR4 or TLR6, but not TLR2, failed to increase expression of these chemokines (Fig. 1a) . Transcriptional upregulation of mRNAs encoding Gro1, MIP-2, MIP-1γ was similarly abolished in macrophages lacking MyD88, whereas oxLDL induction of RANTES mRNA required the alternative TLR adaptor TRIF (Fig. 1b) . In addition to these chemokines, TLR4, TLR6 and MyD88 were also essential for upregulated expression of the mRNA encoding the cytokine interleukin (IL)-1β (Il1b) in response to oxLDL (Fig. 1c) . A notable consequence of MyD88 signaling is the activation of the transcriptional regulator NF-κB. We used a cell-based NF-κB-luciferase reporter assay to determine the requirements for oxLDL signaling via TLR4 and TLR6. Whereas oxLDL was unable to induce expression of a reporter construct driven by an NF-κB response element in HEK293 cells expressing TLR2, TLR4 or TLR6 individually, we observed a sixfold increase in NF-κB activation in cells expressing both TLR4 and TLR6 (Fig. 1d) . The signaling cooperation of TLR4 and TLR6 was specific, as oxLDL did not increase NF-κB-dependent reporter expression in cells coexpressing TLR2-TLR6, TLR2-TLR4 or TLR4-TLR9 (Fig. 1d) . Notably, TLR4-TLR6-mediated NF-κB activation occurred in the absence of MD-2, an essential cofactor of the TLR4 complex that recognizes LPS (Fig. 1d) , and was not augmented by the addition of MD-2 (Fig. 1e) . Moreover, TLR4-TLR6 signaling was not altered in the presence of polymyxin B or the MD-2 inhibitor B-1287, which block the biological effects of LPS (Supplementary Fig. 1 ), further indicating that our observations were not due to LPS contamination. These data demonstrate that TLR4 and TLR6, acting together through MyD88 and TRIF-dependent signaling pathways, are required for macrophage chemokine production in response to atherogenic lipids, invoking the existence of a hitherto undescribed TLR heterodimer.
CD36 is a TLR4-TLR6 coreceptor
To understand how oxLDL acts as a TLR agonist, we tested the roles of CD14 and CD36, two lipid-binding receptors known to be TLRcoreceptors. Notably, whereas the prototypic TLR4 coreceptor CD14 did not augment oxLDL-induced NF-κB activation, CD36 increased NF-κB-driven reporter expression threefold in TLR4-TLR6 expressing cells (Fig. 2a) . Furthermore, as observed in Tlr4 −/− and Tlr6 −/− macrophages, CD36-deficient macrophages did not upregulate Gro1, MIP-2 and RANTES transcription in response to oxLDL (Fig. 2b) . To determine whether CD36 is also required for induction of these inflammatory mediators in vivo, we profiled gene expression in atherosclerosis-prone Apoe −/− and Cd36 −/− Apoe −/− mice fed a Western diet for 12 weeks. Gro1, MIP-2 and RANTES mRNA expression was much lower in the descending aorta of the mice lacking CD36 (Fig. 2c) , which showed a corresponding decrease in atherosclerotic lesion formation ( Supplementary Fig. 2 ). Thus CD36, like MyD88 (ref. 15) , is a key component of the signaling pathway that upregulates the expression of these proatherosclerotic chemokines in vivo. To further explore the role of CD36, TLR4 and TLR6 in promoting macrophage inflammatory responses to oxLDL, we measured the requirement of this signaling complex in the production of reactive oxygen species (ROS). Wild-type macrophages exposed to oxLDL (Fig. 2d) , but not native LDL ( Supplementary Fig. 2 ), showed a robust respiratory burst. Whereas Cd36 −/− , Tlr4 −/− and Tlr6 −/− macrophages showed a competent respiratory burst in response to zymosan, as previously described 8, 11 , these cells failed to produce ROS when stimulated with oxLDL ( Fig. 2d) . Collectively, these data demonstrate that Cd36 −/− macrophages phenocopy Tlr4 −/− and Tlr6 −/− cells, suggesting that these receptors act in a common signaling pathway to initiate macrophage inflammatory responses to oxLDL.
Amyloid- peptide triggers CD36-TLR4-TLR6 signaling
Like atherosclerosis, Alzheimer's disease is characterized by a protracted inflammatory response driven by cells of the monocyte lineage, in the brain called microglia 17 . Moreover, the known inflammatory component of Alzheimer's disease, amyloid-β, has also been shown to bind CD36 (ref.
11). We therefore tested whether fibrillar amyloid-β peptide, amino acids 1-42 (Aβ 1-42 ), could activate TLR4-TLR6 signaling through CD36. Aβ 1-42 induced a 3-5-fold activation of an NF-κB-dependent luciferase gene in HEK293 cells coexpressing TLR4 and TLR6 (Fig. 3a) , whereas the control peptide reverse Aβ 42-1 was unable to activate NF-κB (Fig. 3b) . The extra expression of CD36 in these cells caused a two-to threefold amplification of TLR4-TLR6-signaling; however, activation of NF-κB was not augmented by CD14 (Fig. 3c) . Aβ 1-42 was unable to induce expression of an NF-κB-dependent luciferase gene in HEK293 cells coexpressing other TLR pairs including TLR2-TLR6, TLR2-TLR4 or TLR4-TLR9 (data not shown). These data indicate that CD36 recognition of Aβ 1-42 and oxLDL triggers TLR signaling via a shared pathway. Of note, this cooperation differs from that used by the bacterial ligands of CD36, S. aureus and LTA, which preferentially activate TLR2-TLR6-dependent signaling ( Fig. 3d) , suggesting that endogenous ligands of CD36 specifically trigger the TLR4-TLR6 heterodimer. Moreover, because simultaneous expression of CD36, TLR4 and TLR6 was required for maximal induction of these inflammatory responses, our data suggest that a macromolecular signaling complex containing these molecules mediates the innate immune response to endogenous host ligands.
TLR4-TLR6 signaling promotes microglial activation
In Alzheimer's disease, microglia surrounding amyloid-β-containing plaques acquire an activated morphology and secrete inflammatory mediators, including cytokines and reactive oxygen and nitrogen species that promote the neurotoxicity that is pathognomonic of this disease 17 . To determine whether signaling through CD36-TLR4-TLR6 is involved in the activation of microglia by amyloid-β, we generated mouse microglial cell lines deficient in CD36, TLR2, TLR4 and TLR6. Functional characterization of these microglial cell lines showed that they were similar to primary mouse microglial preparations in morphology, expression of cell surface markers and function, including appropriate TLR responses to microbial ligands ( Supplementary Fig. 3 and ref. 18 ). Consistent with published reports, Aβ 1-42 induced secretion of nitric oxide and ROS by wild-type microglial cells (Fig. 4a-c) .
Notably, these inflammatory responses were abrogated in microglia deficient in CD36, TLR4 or TLR6, but not TLR2 (Fig. 4a,c) . Moreover, Aβ 1-42 induced secretion of NO in Md2 −/− (also known as Ly96 −/− ) microglia was comparable to that in wild-type microglia, whereas these cells showed impaired NO production when stimulated with LPS (Fig. 4b) . These findings provide functional evidence of the importance of the CD36-TLR4-TLR6 signaling complex in regulating the microglial innate immune response to Aβ 1-42 .
TLR4-TLR6 activation primes microglia for IL-1 production
A critical component of the microglial inflammatory response to amyloid-β is the secretion of the inflammatory cytokine IL-1β (ref. 18) . Elevated amounts of this cytokine are detected in the brains and cerebrospinal fluid of individuals affected by Alzheimer's disease 17 . We previously established that CD36 is required for Aβ 1-42 upregulation of IL-1β mRNA by microglia 11 , and thus we sought to determine whether TLR4-TLR6 signaling is involved in the initiation of this response. Wild-type microglia exposed to Aβ 1-42 showed a fourfold increase in Il1b mRNA (Fig. 4d) . Notably, we observed no increase in Il1b mRNA expression in similarly treated Tlr4 −/− , Tlr6 −/− and Myd88 −/− microglia, indicating an essential role for these components in the signaling cascade leading to Il1b mRNA upregulation (Fig. 4d) . In contrast, whereas TRIF was not required for Aβ 
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-/-WT Tlr4 (Fig. 4d) , it was essential for TLR4-TLR6-dependent induction of the chemokine RANTES by Aβ (Fig. 4e) .
Because IL-1β, as well as NO and ROS, has been implicated in the cytotoxic effects of amyloid-β on surrounding neurons 18, 19 , we tested whether Aβ 1-42 -CD36-TLR4-TLR6 signaling in microglia would promote neuronal dysfunction. As reported previously, incubation of a mouse neuronal cell line with Aβ 1-42 alone induced only minimal morphological effects (data not shown) 18 . However, Aβ 1-42 induced widespread neuronal cell death in cocultures of neurons and wild-type microglial cells (Fig. 4f) . In marked contrast, no neurotoxic effects of Aβ were observed in such cocultures containing Tlr4 −/− and Tlr6 −/− microglia, consistent with the failure of these microglia to produce IL-1β, NO and ROS (Fig. 4f) . Notably, neurons in cocultures containing Tlr2 −/− microglia were not protected from Aβ 1-42 -induced cell death. Taken together, these data indicate that TLR4-TLR6 signaling promotes microglial inflammatory responses associated with Alzheimer's disease pathology and link sterile inflammation in atherosclerosis and Alzheimer's disease to the activation of a common signaling complex composed of CD36, TLR4 and TLR6.
CD36 regulates TLR4-TLR6 complex formation
To understand how this heterotrimeric signaling complex assembles, we examined by immunoprecipitation the association of CD36, TLR4 and TLR6 in THP-1 monocytes stimulated with oxLDL or Aβ . Stimulation of THP-1 monocytes with CD36 ligands rapidly induced formation of complexes yielding coprecipitation of CD36 with TLR4 and TLR6 (Fig. 5a,b) . To further define the interaction of CD36, TLR4 and TLR6, we examined the localization of these receptors by confocal microscopy in HEK293 cells transfected with the receptors. Minimal colocalization of CD36, TLR4 and TLR6 was seen in resting cells, but upon treatment with oxLDL, CD36, TLR4 and TLR6 colocalized predominantly in intracellular compartments (Fig. 5c ). This intracellular colocalization prompted us to test whether endocytosis of oxLDL or Aβ 1-42 was required for signaling via this complex. CD36 and TLR4 are both internalized from the plasma membrane through dynamindependent endocytosis that can be specifically blocked using the inhibitor Dynasore 20, 21 . Treatment of macrophages with Dynasore blocked oxLDL uptake and the induction of chemokine expression (Fig. 5d) , suggesting that signaling from the CD36-TLR4-TLR6 complex also requires dynamin-dependent endocytosis. Moreover, Dynasore treatment of microglia abolished upregulation of Il1b mRNA by Aβ ( Fig. 5e) , consistent with the idea that signaling from the CD36-TLR4-TLR6 complex is triggered upon ligand internalization.
To further explore how CD36 regulates TLR4-TLR6 complex formation, we mutated CD36 to identify regulatory sequences essential for TLR4-TLR6 activation. Notably, mutation of the CD36 cytoplasmic C terminus, a domain postulated to interact with kinases, abrogated oxLDL-induced signaling. While not altering cell surface localization of CD36, selective replacement of residues 460-472 with alanines (CD36 Ala ) impaired the ability of CD36 to induce NF-κB-dependent luciferase gene expression in HEK293 cells coexpressing TLR4 and TLR6 (Fig. 6a) . Furthermore, mutation of Tyr463, but not the adjacent cysteine (Cys464) within this domain of CD36, blocked ligand-induced NF-κB activation (Fig. 6a) . Tyr463 of CD36 was also required for TLR4-TLR6 coprecipitation (Fig. 6b) . Whereas oxLDL markedly augmented coprecipitation of TLR4 and TLR6 in HEK293 cells coexpressing wild-type CD36, coexpression of CD36 Y463F with these TLRs was insufficient to induce association of TLR4 with TLR6 (Fig. 6b) . These data identify Tyr463 of CD36 as a critical regulator of TLR4-TLR6 dimerization and signaling. 
A r t i c l e s
We next sought to identify potential interacting partners for this domain using His-tagged peptides corresponding to the native CD36 C terminus (residues 460-472) or a scrambled version. Immunoblotting of proteins precipitated with these peptides identified three main phosphotyrosine proteins that bound the native CD36 C-terminal peptide but not a scrambled version: FAK (125 kDa), Paxillin (68 kDa) and a protein of approximately 60 kDa (Supplementary Fig. 4 ). Using HEK293 cells overexpressing CD36 as a model system, we identified this ~60-kDa CD36-binding protein as the kinase Lyn. As observed in macrophages 12 , CD36 immunoprecipitated preferentially with Lyn, but not with Src, the prototypic kinase in the Src family (Fig. 6c) . A peptide corresponding to the C terminus of CD36 was sufficient to mediate the interaction with Lyn, and, as shown by peptide competition, this binding required the MISY motif (amino acids 460-463) encompassing Tyr463 (Fig. 6c) .
To test the functional role of Lyn in CD36-TLR4-TLR6 signaling, we assessed the effect of tyrosine kinase inhibitors on NF-κB activation and CD36-TLR4-TLR6 complex formation. The general tyrosine kinase inhibitor genistein, but not its inactive analog daidzen or inhibitors of phosphatidylinositol-3-OH kinase (LY294002 and wortmannin), blocked CD36-TLR4-TLR6-dependent activation of NF-κB reporter gene expression (Fig. 6d) . Notably, treatment with the Lyn kinase inhibitor PP1, but not the inactive analog PP3, replicated these inhibitory effects on CD36-TLR4-TLR6 signaling and blocked the physical association of CD36 with TLR4 and TLR6 in oxLDL-treated monocytes (Fig. 6d,e) . Collectively, these data support a role for CD36-Lyn kinase interactions initiated at Tyr463 in facilitating TLR4-TLR6 heterodimerization and signal initiation. Because Lyn is implicated in the phosphorylation of the TLR4 TIR domain and activation of TLR4 signal transduction 22 , we postulate that CD36 delivery of Lyn during complex formation may promote TLR4-TLR6 signaling in a similar manner.
DISCUSSION
The discovery of mammalian TLRs and their critical role in detecting pathogen-associated molecular patterns has greatly expanded our understanding of the innate immune response to infection. By contrast, the molecular mechanisms underlying sterile inflammatory conditions remain less well understood. Atherosclerosis and Alzheimer's disease are characterized by a protracted sterile inflammatory response in which cells of the monocyte lineage accumulate prominently in plaques that underlie the pathology of these diseases 14, 17 . A common characteristic of these age-related diseases is the anomalous deposition of modified self components in affected tissues: oxidized LDL and amyloid-β peptide accumulate in plaques of the artery wall and brain respectively, and are believed to fuel the recruitment and activation of mononuclear cells.
Our work identifies a previously undescribed TLR heterodimer composed of TLR4 and TLR6 that senses these endogenous ligands and initiates innate immune activation of macrophages and microglia. Notably, this pathway is triggered through binding of atherogenic lipids and amyloid-β to a shared receptor, CD36, that provides the proximal signaling event required for TLR4-TLR6 activation. Together, this heterotrimeric signaling complex regulates the expression of proinflammatory mediators directly implicated in the deleterious effects of these modified self components in vivo, including chemokines and reactive oxygen and nitrogen species. Additionally, CD36-TLR4-TLR6 signaling in macrophages and microglia results in transcription of mRNA encoding pro-IL-1β, priming these cells for inflammasome activation and IL-1β secretion. This work thus provides the molecular mechanism of how these endogenous ligands can act as TLR ligand mimetics and identifies a common means for chronic mononuclear cell activation in two important, age-related, chronic inflammatory diseases.
Targeted deletion of the TLR adaptor MyD88 in a mouse model of atherosclerosis causes a severe reduction in atherosclerotic lesion size, attributable in part to decreased chemokine expression in the aorta 15 . Upstream activation of TLR4 or TLR2 has been implicated in this MyD88-dependent inflammation of the artery wall 16, 23, 24 ; however, the mechanism by which these microbial sensing pathways are triggered and the ligands responsible were not known. Notably, we found that oxLDL-induced CD36-TLR4-TLR6 signaling in macrophages triggered a MyD88-dependent chemokine signature similar to that observed in vivo, and furthermore elicited expression of the TRIF-dependent chemokine RANTES. Consistent with these findings, expression of these chemokines was reduced in the aortas of hyperlipidemic Apoe −/− mice lacking CD36, emphasizing the important role of this coreceptor in facilitating TLR4-TLR6 signaling. In addition to oxLDL-induced chemokine expression, MyD88-dependent signaling initiated by CD36-TLR4-TLR6 activates the macrophage respiratory burst and production of reactive oxygen species. This innate defense function of macrophages amplifies oxidative stress in the artery wall, thereby promoting the generation of oxidized lipoprotein ligands and chronic macrophage activation. Our identification of a CD36-TLR4-TLR6 complex that regulates these inflammatory responses to oxidized LDL thus provides mechanistic insight into how MyD88-dependent signaling is triggered during atherogenesis.
The inflammatory cytokine IL-1β is found prominently in atherosclerotic and Alzheimer's disease plaques 14, 17 , and targeted inhibition of this cytokine reduces markers of disease 18, 25, 26 . The secretion of IL-1β is a two-step process requiring both upregulation of Il1b transcription by NF-κB and activation of a cytosolic multiprotein complex called the inflammasome that processes pro-IL-1β protein to its mature form 27 . The recent identification of amyloid-β peptide 18 and cholesterol crystals (E. Latz, personal communication) as activators of the NALP-3 inflammasome has emphasized the importance of understanding the regulation of pro-IL-1β expression in atherosclerosis and Alzheimer's disease. Monocytes deficient in CD36 show impaired IL-1β expression in response to oxLDL and amyloid-β 10,11 . Our work now identifies TLR4-TLR6 as crucial components of the signaling pathway that primes macrophages and microglia for pro-IL-1β expression. These data identify signaling through the newly identified CD36-TLR4-TLR6 complex as the 'first hit' in the induction of this highly regulated cytokine, and we show that disruption of TLR4-TLR6 signaling in microglia abrogates IL-1β, nitric oxide, and ROS production and protects surrounding neurons from amyloid-β-induced death. TLR4 expression in the brain is increased in a mouse model of Alzheimer's disease 28 , and, consistent with our model, targeted deletion of TLR4 blocks the increase in cerebral IL-1β amounts and microglial production of nitric oxide 28, 29 . Although the role of IL-1β and neuroinflammation in Alzheimer's disease remains controversial 30 , it is noteworthy that a TLR4 polymorphism that attenuates receptor signaling (D299G) is associated with decreased risk of atherosclerosis, acute coronary events and Alzheimer's disease [31] [32] [33] .
Although we focus on two endogenous ligands involved in sterile inflammatory processes, this TLR heterodimer may also recognize as yet unidentified pathogen-associated molecular patterns, as several microbial ligands for CD36 have been identified 4, 5 . Moreover, this work has also yielded some generally applicable insights into TLR recognition. First, our work identified a TLR heterodimer composed of TLR4-TLR6. We found that atherogenic lipids and amyloid-β initiated signaling that required coexpression of both TLR4 and TLR6, and was independent of known components of the TLR4 homodimeric complex, such as MD-2 and CD14. This signaling led to the expression of both MyD88-and TRIF-dependent genes, A r t i c l e s indicating that TLR4-TLR6 engages both of these adaptor pathways. Second, our data suggest a new model of TLR heterodimerization in which dimer assembly and activation is regulated by signaling initiated from a cell surface coreceptor, CD36. Coimmunoprecipitation assays showed a ligand-dependent physical association of TLR4 and TLR6, requiring expression of functional CD36. The early description of TLR2-TLR1 and TLR2-TLR6 heterodimers led to the speculation that heterodimerization might further diversify the TLR repertoire 3 . However, it is noteworthy that no other heterodimers with ascribed ligands have since been described. Our identification of a TLR4-TLR6 heterodimer was only made possible because of coexpression with the relevant coreceptor, CD36, which was required for its activation. Although several TLR coreceptors, such as CD14 and the vitronectin receptor, have been suggested to concentrate microbial molecules and deliver them to pattern-recognition complexes 2, 6 , our data indicate a more active role for CD36 in modulating TLR4-TLR6 signal transduction. The signals that induce TLR4-TLR6 heterodimerization occurred from the C terminus of CD36 within the cell, leading us to compare this to the 'inside-out' signaling described for integrins 34 . Our data are consistent with TLR4-TLR6 signaling being triggered by a proximal membrane event initiated by CD36 interaction with Lyn kinase. This model is supported by the following observations: first, mutation of Tyr463 of CD36 blocked its ability to induce TLR4-TLR6 heterodimerization and NF-κB activation; second, Tyr463 of CD36 regulated its interaction with Lyn kinase; third, chemical inhibitors of Lyn kinase blocked CD36 ligand-induced TLR4-TLR6 association and activation of NF-κB; and fourth, Lyn-deficient macrophages show impaired responses to amyloid-β, including the production of ROS 12 . Because tyrosine phosphorylation of the TIR domain of TLR4 is required for LPS signaling 22 , we suggest that, through recruitment of Lyn kinase, CD36 may similarly promote TLR4 and/or TLR6 phosphorylation and activation. This model highlights the importance of coreceptor function in triggering TLR4-TLR6 signaling and suggests that other TLR heterodimers may be identified if, as we demonstrate herein, the TLRs are coexpressed with their relevant coreceptors.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
